Press release
Bladder Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Explore our latest breakthroughs in Bladder Cancer Research. Learn more about our innovative pipeline today! @ Bladder Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Bladder Cancer Pipeline Report
* In March 2025, Janssen Research & Development LLC announced a phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy.
* In March 2025, Fidia Farmaceutici announced a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or without concomitant Ta-T1, who are unresponsive to BCG therapy and unwilling or unfit to undergo radical cystectomy.
* In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive and cancer free longer than those who receive placebo and pembrolizumab, and to learn about the safety of V940, pembrolizumab, and EV, and if people tolerate them.
* DelveInsight's Bladder Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Bladder Cancer treatment.
* The leading Bladder Cancer Companies such as UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc ., and others.
* Promising Bladder Cancer Therapies such as Atezolizumab, PGV001, VAX014, BCG Vaccine, Oncofid-P-B, Oncofid-P-B, and others.
Stay informed about the cutting-edge advancements in Bladder Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Bladder Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bladder cancer Emerging Drugs Profile
* UGN-102: UroGen Pharma Ltd.
UGN-102 (mitomycin) for intravesical solution is an investigational drug formulation of mitomycin. It is been developed by utilizing UroGen's proprietary RTGel Registered technology which is a sustained release, hydrogel-based formulation, UGN-102 is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. UGN-102 is delivered to patients using a standard urinary catheter in an outpatient setting. Currently it is in Phase III stage of clinical trial for the treatment of Bladder Cancer.
* APL 1202 : Asieris Pharmaceuticals
APL-1202 is an orally available reversible MetAP2 Inhibitor with anti-angiogenic, anti-tumor activities and can also modulate tumor immune microenvironment. It is currently in registration clinical trials in China, either as single agent as first-line treatment for patients with intermediate-risk non-muscle invasive bladder cancer (NMIBC), or in combination with a chemotherapy as second-line treatment in patients with intermediate and high-risk chemo-refractory NMIBC. Currently, the drug is being evaluated in the Phase III stage for Bladder Cancer.
* Trilaciclib: G1 Therapeutics, Inc.
Trilaciclib, is a first-in-class therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. It is a transient IV-administered CDK4/6 inhibitor, a novel therapeutic approach which is given before chemotherapy that temporarily blocks progression through the cell cycle. Currently the drug is being evaluated in Phase II for the treatment of Bladder Cancer.
* Catumaxomab: LintonPharm Co.,Ltd.
Catumaxomab is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through FcR binding at the same time. The drug kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. The drug is in Phase I/II stage of clinical trials for the treatment of bladder cancer.
* VAX 014: Vaxiion Therapeutics
VAX014 is a novel rBMC-based oncolytic immunotherapy. VAX014is a first-in-class tumor-targeted oncolytic agent based on Vaxiion's proprietary rBMC technology. It works by specifically targeting and delivering a novel fast-acting pre-formed oncolytic protein toxin directly to tumor cells that express either 31 or 51 integrin(s), both commonly found to be selectively expressed in many solid tumor types. The drug is in Phase I stage of clinical trials for the treatment of bladder cancer.
Learn more about Bladder Cancer Drugs opportunities in our groundbreaking Bladder Cancer Research and development projects @ Bladder Cancer Unmet Needs [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bladder Cancer Companies
UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others.
Bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
Bladder Cancer Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Discover the latest advancements in Bladder Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Bladder Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Bladder Cancer Pipeline Report
* Coverage- Global
* Bladder Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Bladder Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Bladder Cancer Companies- UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology, Inc., Ferring Pharmaceuticals, SURGE Therapeutics, Halozyme Therapeutics, ImmunityBio, Inc., AstraZeneca, Spectrum Pharmaceuticals, Inc., enGene, Inc., CicloMed LLC, Protara Therapeutics, Hoffmann-La Roche, Astellas Pharma Global Development, Inc., and Five Prime Therapeutics, Inc., and others
* Bladder Cancer Therapies- Atezolizumab, PGV001, VAX014, BCG Vaccine, Oncofid-P-B, Oncofid-P-B, and others.
For a detailed overview of our latest research findings and future plans, read the full details of Bladder Cancer Pipeline on our website @ Bladder Cancer Drugs and Companies [https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Bladder Cancer Executive Summary
* Bladder Cancer: Overview
* Bladder Cancer Pipeline Therapeutics
* Bladder Cancer Pipeline Therapeutic Assessment
* Late Stage Products (Phase III)
* UGN-102: UroGen Pharma Ltd.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Trilaciclib: G1 Therapeutics, Inc.
* Early Stage Products (Phase I)
* VAX 014: Vaxiion Therapeutics
* Inactive Products
* Bladder Cancer Key Companies
* Bladder Cancer Key Products
* Bladder Cancer - Unmet Needs
* Bladder Cancer - Market Drivers and Barriers
* Bladder Cancer - Future Perspectives and Conclusion
* Bladder Cancer Analyst Views
* Bladder Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bladder-cancer-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bladder Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3937337 • Views: …
More Releases from ABNewswire
New Children's Book "Zachary and Ombu" Weaves Magic, Friendship, and Gentle Less …
New Picture Book Weaves Gentle Lessons on Bravery and Resilience with a Heartwarming Adventure, Inspiring a Lifelong Love of Nature and Learning in Children
What happens when a little boy with a big imagination meets a tiny dinosaur in boots, under a tree that follows them through the jungle? You get an adventure that's as unexpected as it is unforgettable. In her delightful new picture book, Zachary and Ombu Explore the…
Cglow Skincare Revolutionizes Holiday Beauty Shopping with Professional-Grade Or …
Certified holistic health practitioner Cheryl Siverling's Cglow Skincare offers proven organic alternatives to conventional beauty products. Drawing on 26 years of cosmetology expertise, the new brand delivers whole-body skincare solutions that don't compromise between clean ingredients and visible results.
Cglow Skincare transforms the organic beauty landscape as founder Cheryl Siverling leverages her unique combination of 26 years cosmetology experience and holistic health certification to create skincare products that meet professional standards…
Newrest Family Funerals Expands Nationwide Direct Cremation Services with Afford …
Newrest Family Funerals announces the expansion of its affordable Direct Cremation service across England and Wales, offering families a dignified, low-cost funeral option with 24/7 support. Prices start at just 1,195.
Stevenage, Hertfordshire, U.K. - Newrest Family Funerals, a long-established and family-run funeral provider, is proud to announce the expansion of its Direct Cremation services across England and Wales. Designed to give families a dignified yet affordable option, Direct Cremation is…
Birdfy Black Friday 2025: Get Exclusive Discounts on Innovative Bird Feeder Came …
Image: https://www.abnewswire.com/upload/2025/11/a9c285d8c92fcf546147a0c329f7a311.jpg
Black Friday bird feeders from Birdfy make birdwatching more fun over the holiday season. With its smart bird feeder cameras and other products inspired by nature, Birdfy is a market pioneer that invites everyone to enjoy tech-savvy birdwatching. Whether you want to bring some vibrant birds into your backyard or give nature enthusiasts something unique, their products can be the ideal option.
This year's Birdfy Black Friday [https://www.birdfy.com/pages/black-friday] offers unbeatable…
More Releases for Bladder
Growing Demand For Bladder Cancer Drugs: The Driving Engine Behind Bladder Cance …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Bladder Cancer Drugs Market Size Growth Forecast: What to Expect by 2025?
In recent years, the bladder cancer drugs market has experienced a swift expansion. The market size is projected to increase from $4.26 billion in 2024 to $4.94 billion in 2025, achieving a compound annual growth rate (CAGR)…
Rising Prevalence Of Pediatric Bladder Disorders Fuels Growth In The Pediatric B …
The Pediatric Bladder Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Pediatric Bladder Treatment Market?
The market size for pediatric bladder treatment has been expanding significantly in the past few years. The anticipated rise is from $3.54 billion…
Emerging Trends Influencing The Growth Of The Overactive Bladder Treatment Marke …
The Overactive Bladder Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Overactive Bladder Treatment Market?
The market size for overactive bladder treatments has been consistently expanding over the past few years. The market is projected to increase from…
Transforming the Pediatric Bladder Treatment Market in 2025: Rising Prevalence O …
What Is the Expected Size and Growth Rate of the Pediatric Bladder Treatment Market?
The pediatric bladder treatment market has grown steadily in recent years. It will increase from $3.54 billion in 2024 to $3.73 billion in 2025, at a CAGR of 5.1%. The growth is due to the prevalence of pediatric bladder conditions, growing awareness of such conditions, improved access to healthcare for children, and rising disposable incomes.
The pediatric bladder…
diaphragm accumulator, bladder accumulator ,ball valve, bladder
Siken Hydraulics Inc. has a team of industry experts with experiences over 20 years ,who are always willing to serve the clients all the time. We could design and offer our hydraulic accumulator, pulsation dampeners, compensators according to different standards such as ASME, CE/PED etc.to meet our customers' diverse needs for our products.
We are providing the piston accumumulator from 0.1L to 500L and operating pressures up to 20,000…
Overactive Bladder Market - Empowering Life Without Limits: Overactive Bladder S …
Newark, New Castle, USA - new report, titled Overactive Bladder Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Overactive Bladder market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Overactive Bladder market. The report offers an overview of the market, which…
